The pre seed round was led by Episode 1 Ventures and will support infrastructure development and team expansion.
"We are really excited, this investment will help Sable Bio redefine drug safety assessment and change the ways actionable biomedical insights are generated. Working with with leading investors Episode 1 and Seedcamp is enabling us to build an exceptional team and a platform to accelerate safer drug development for patients in need"
The funding round includes a grant from Innovate UK and strategic backing from Modality Partnership to develop hypertension and mental health services.
"Over 30% of hypertension patients are affected by anxiety or depression, impacting their ability to manage lifestyle behaviours consistently. At Holly Health, we have supported over 30,000 people so far and are committed to innovating to solve our biggest human and healthcare challenges. This funding marks a pivotal moment – with the support of Innovate UK and the strategic investment from Modality Partnership, we are empowered to combat the complex and unresolved challenge of multimorbidity."
The funding will support the clinical progression and regulatory advancement of the company proprietary nanoclay platform.
"advancing the development of [their] orthobiologics product, RENOVITE® nanoclay, and progressing through regulatory milestones to get this technology closer to clinic and spinal fusion patients."